# Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®

> **NCT00256126** · PHASE4 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 318 (actual)

## Conditions studied

- Growth Hormone Deficiency
- Turner Syndrome

## Interventions

- **DRUG:** Saizen
- **DRUG:** Saizen

## Key facts

- **NCT ID:** NCT00256126
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05-31
- **Primary completion:** 2007-09-30
- **Final completion:** 2007-09-30
- **Target enrollment:** 318 (ACTUAL)
- **Last updated:** 2018-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00256126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00256126, "Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00256126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*